The collaboration between Ipsen and Resilience Care aims to evaluate, through a national multicenter retrospective real-world study, the clinical benefits of combination therapies in first-line metastatic Renal Cell Carcinoma (mRCC) care. Both companies share a commitment to innovation that creates meaningful impact for patients and healthcare professionals.

A First Large-Scale Retrospective Study to Evaluate Combination Therapies in Real-World Settings*

An estimated 17,141 new cases of kidney cancer were diagnosed in France in 2023, marking a striking 199% increase in incidence between 1990 and 2023 [1] — with 10% to 40% at metastatic stage (mRCC) [2]. In recent years, patient prognosis has significantly improved thanks to the emergence of innovative treatments such as immunotherapy and antiangiogenic agents [3]. The combination of these therapies is now a first-line therapeutic strategy [3]. However, despite these major therapeutic advances, real-world evidence on their clinical benefits and effectiveness in routine practice remains limited.

In this context, Resilience Care and Ipsen have decided to join forces to launch the first national multicenter retrospective real-world study aimed at evaluating the clinical benefits of combination therapies in first-line metastatic Renal Cell Carcinoma (mRCC) care*. The goal is to address essential clinical questions by harnessing a high-quality, representative real-world database to understand the real-word use, effectiveness, and benefits of combination therapies in routine clinical practice.

This first national large-scale study will be conducted over one year across 24 centers in France (university hospitals, comprehensive cancer centers, and public/private centers) involving 400 patients with metastatic kidney cancer who have started combination therapy in first line.

A renowned Scientific Committee ensures the quality and scientific relevance of the project. It is composed of:

• Pr. Laurence Albigès, Head of the Medical Oncology Department (Institut Gustave Roussy)
• Dr. Philippe Barthelemy, Medical Oncologist (ICANS & CHRU Strasbourg)
• Dr Delphine Borchiellini, Medical Oncologist (Centre Antoine Lacassagne)

‍

From Clinical Care to Research

Resilience Care brings three  innovative technological and structural levers to this collaboration, enabling to build this high-quality, representative real-world evidence database for patients with metastatic kidney cancer:

• Natural Language Processing (NLP): It enables automatic collection and structuring of clinical data from Electronic Health Records and routine care documents (medical and imaging reports, prescriptions, laboratory results, etc.). This technology reduces time-consuming manual data entry and alleviates the administrative burden of data collection for healthcare professionals.
• Longitudinal Patient-Reported Outcomes (PROs) data: Collected through the patient application to continuously monitor the evolution of patients' health status  and capture their day-to-day experience.
• A strong territorial network: Resilience Care leverages a representative network of over 170 partner healthcare facilities [4], ensuring geographic and typological representation across the 24 centers participating in the study.

‍

A Shared Commitment to Patient-Centered Innovation

Ipsen is a major player committed to accelerating research through real-world data and artificial intelligence technologies. Resilience Care shares with the pharmaceutical group a strong commitment to innovation for patients and healthcare professionals.

This partnership strengthens Resilience Care's leading role in real-world research and fully aligns with its approach: placing data at the heart of care and research to precisely understand each patient and deliver the right care at the right time.

‍

Sources

[1] Lapôtre-Ledoux B., Remontet L., Uhry Z., Dantony E., D’Almeida T. Incidence des principaux cancers en France métropolitaine en 2023 et tendances depuis 1990 Bull Epidemiol Hebd 2023 ;  12 : 188-204

[2] C. Rolley, C. Aubert, N. Baize, P. Bigot. Prise en charge des métastases du cancer du rein. Progrès en Urologie, Volume 28, Issue 14, 2018, Pages 777-782, ISSN 1166-7087. https://doi.org/10.1016/j.purol.2018.07.280.

[3] Powles, T., et al. "ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma." Annals of Oncology 32.12 (2021): 1511-1519.

[4] Resilience Care Internal Data — updated 02/2026

‍

* First national retrospective study, the only other real-world study on the subject being CABOCOMBO, a phase IV prospective study